ARTICLE | Product Development
China’s biosimilars in fast lane
Guest Commentary: Why China's biosimilars market could take off faster than the U.S.'s and Europe's
August 16, 2019 11:49 PM UTC
Though coming from behind, China is cracking the seal on its biosimilar market and may even be poised to over-take the U.S. and Europe in less than a decade.
On February 22, 2019, China’s National Medical Products Administration (NMPA) approved the country’s first biosimilar, Rituximab from Shanghai Henlius Biopharmaceuticals Co Ltd. ...